Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track OABI with free AI briefings, catalyst countdowns, and dilution alerts.

OABI · OmniAb, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$64.2M Cash on Hand
CF+ Cash Runway
Follow OABI by email Get an email when OABI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about OABI, unsubscribe in one click. Privacy

📣 What OABI Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

OABI holds $64.2M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OABI files for a raise →

👥 Who Owns OABI

Insiders 5.8% Institutions (199 holders) 53.4% Public and other holders 40.8%
HolderTypeShares% of sharesAs of
Robert Goldstein Institution (13G, 5%+) 12,291,972 8.43% 2025-12-31
Whitefort Capital Management, LP Institution (13G, 5%+) 10,248,658 7.03% 2026-06-30
Matthew W Foehr
President and CEO, Director · +1.87M options
Insider 4,420,492 3.03% 2026-04-07
John L Higgins
Director · +100,000 options
Insider 2,962,320 2.03% 2026-06-17
Charles S Berkman
Chief Legal Officer · +711,042 options
Insider 399,085 0.27% 2026-04-07
Kurt A Gustafson
Executive VP, Finance and CFO · +711,042 options
Insider 261,483 0.18% 2026-04-07
Jennifer R. Cochran
Director · +100,000 options
Insider 185,274 0.13% 2026-06-17
Carolyn R Bertozzi
Director · +100,000 options
Insider 113,308 0.08% 2026-06-17
Steven Love
Director · +100,000 options
Insider 105,000 0.07% 2026-11-01
Steven C. Crouse
Director · +206,667 options
Insider 33,333 0.02% 2026-06-17
Philip J Gotwals
Director · +206,667 options
Insider 33,333 0.02% 2026-06-17

Share count 145,860,318 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full OABI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OABI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.